QualityStocksNewsBreaks – Endonovo Therapeutics Inc.’s (ENDV) SofPulse(R) Reduces Opioid Prescriptions at New Hanover Regional Medical Center

Commercial-stage developer of innovative medical devices Endonovo Therapeutics (OTCQB: ENDV) was recently featured in a Wect.com article by Jack Bailey titled, ‘Medical device lowers opioid prescriptions at NHRMC’. The article highlights ENDV’s noninvasive Electroceutical(R) therapeutic device, SofPulse(R). According to the article, surgeons at New Hanover Regional Medical Center are utilizing SofPulse(R) as an alternative to narcotics to treat patients’ pain. SofPulse(R) works by using electromagnetic waves to lower inflammation and accelerate the recovery process. NHRMC urologist Dr. Roc McCarthy pointed out there has been a 30%-40% decline in post-op narcotic prescriptions since they began using the device six months ago. “It’s just opening the door to a world of opportunity for people to come up and innovate other ways of decreasing the amount of pain that people are having,” Dr. Roc McCarthy stated in the article.

To view the full article, visit http://ibn.fm/Gjltn

About Endonovo Therapeutics

Endonovo Therapeutics is a commercial-stage developer of noninvasive, wearable Electroceuticals(R) therapeutic devices. The company’s current portfolio of commercial and clinical-stage wearable Electroceuticals(R) therapeutic devices addresses wound healing, pain, postsurgical pain and edema, cardiovascular disease, chronic kidney disease, and central nervous system (“CNS”) disorders including traumatic brain injury (“TBI”), acute concussions, post-concussion syndrome and multiple sclerosis. The company’s noninvasive Electroceutical(R) therapeutic device, SofPulse(R), which uses pulsed short-wave radiofrequency at 27.12 MHz, has been FDA cleared and CE marked for the palliative treatment of soft-tissue injuries and postoperative pain and edema and has CMS national coverage for the treatment of chronic wounds. The company’s current portfolio of preclinical-stage Electroceuticals(R) therapeutic devices addresses chronic kidney disease, liver-disease nonalcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD), and ischemic stroke. The company’s noninvasive, wearable Electroceuticals(R) therapeutic devices work by restoring key electrochemical processes that initiate anti-inflammatory and growth-factor cascades necessary for healing to occur. For more information, visit the company’s website at www.Endonovo.com.

NOTE TO INVESTORS: The latest news and updates relating to ENDV are available in the company’s newsroom at http://ibn.fm/ENDV

About QualityStocksNewsBreaks

QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php